It's no longer enough to evaluate Allergan's (NYSE: AGN )
earnings on a stand-alone basis; almost everything that happens with
or to Allergan these days is going to be viewed through the lens of how
it impacts Valeant's (NYSE: VRX )
hostile bid for the company and Allergan's efforts to resist that bid.
Although Allergan's recent R&D update was not uniformly positive,
today's earnings and guidance do serve to raise the stakes a bit, and
Valeant's recent complaints to regulators tell me that Allergan has
scored a few hits with its own PR program.
Follow this link for more:
Allergan Stock Earnings: Good Enough to Fight off Valeant?
No comments:
Post a Comment